Last edition
News about "biologic therapy"
Johnson & Johnson’s IL-23 inhibitor becomes the first in its class to include evidence of structural joint damage inhibition in adults with active psoriatic arthritis.
Biologic Therapy | 30/05/2026 | By News Bureau
AstraZeneca Wins US Approval for Self-Administered Saphnelo Pen for Lupus Treatment
AstraZeneca launches a self-injectable version of Saphnelo, offering lupus patients a more convenient treatment option with proven efficacy and safety.
Biologic Therapy | 28/04/2026 | By News Bureau | 123
Adimab Collaborator GSK Receives Additional Marketing Approval for Depemokimab
Adimab Collaborator GSK has received additional marketing approval for depemokimab, marking the sixth collaborator program to reach the market and strengthening its biologics portfolio.
Biologic Therapy | 17/04/2026 | By News Bureau
European Commission Approves Dupixent for Young Children with Chronic Spontaneous Urticaria
The European Commission has expanded approval of Dupixent to children aged 2–11 with chronic spontaneous urticaria, offering a targeted treatment for those unresponsive to standard antihistamines.
Biologic Therapy | 15/04/2026 | By News Bureau | 103
Sanofi's Lunsekimig Shows Promising Phase II Results in Asthma and Nasal Polyps Studies
The novel dual-targeting Nanobody met primary and key secondary endpoints in asthma and chronic rhinosinusitis trials, demonstrating improved outcomes and a favourable safety profile.
Biologic Therapy | 08/04/2026 | By News Bureau
Eli Lilly and Company's Ebglyss Shows Four-Year Durable Relief in Atopic Dermatitis Study
Long-term phase III data reveal sustained skin clearance and itch reduction with once-monthly dosing in eczema patients.
Biologic Therapy | 30/03/2026 | By News Bureau | 110
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy